Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- , (Nasdaq: TVTX) ...
Akebia Therapeutics®, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of ...
State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic & Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, ...
The findings are significant for the liver research community and others interested in the gut-liver axis. (A) AOAH cleaves the two piggyback fatty acyl chains from the lipid A moiety, inactivating ...